| Maame Efua Sampah, MD PHD | |
|
3800 Reservoir Rd Nw, Washington, DC 20007-2113 | |
| (202) 877-7000 | |
| Not Available |
| Full Name | Maame Efua Sampah |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | 3800 Reservoir Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134542319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD210012023 (District Of Columbia) | Secondary |
| 208600000X | Surgery | MTL003676 (District Of Columbia) | Primary |
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124009758 PECOS PAC ID: 4981745098 Enrollment ID: O20131125000833 |
News Archive
"Global progress in both preventing and treating HIV emphasizes the benefits of sustaining investment in HIV/AIDS over the longer term," according to a new report from the WHO, UNICEF and UNAIDS, which also "indicates that increased access to HIV services resulted in a 15 percent reduction of new infections over the past decade and a 22 percent decline in AIDS-related deaths in the last five years," a WHO press release reports.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme, the most malignant cancer of the brain.
Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Spectranetics Corporation today initiated a voluntary recall of specific lots of its thrombus extraction catheter (product number 60090-01) manufactured by Spectranetics since October 2009. The Food and Drug Administration has been informed of this action and communication to various Competent Authorities outside of the United States has begun. While Spectranetics has received and confirmed customer complaints on this issue, no adverse events have been reported to the Company.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maame Efua Sampah, MD PHD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-2704 | Maame Efua Sampah, MD PHD 3800 Reservoir Rd Nw, Washington, DC 20007-2113 Ph: (202) 877-7000 |
News Archive
"Global progress in both preventing and treating HIV emphasizes the benefits of sustaining investment in HIV/AIDS over the longer term," according to a new report from the WHO, UNICEF and UNAIDS, which also "indicates that increased access to HIV services resulted in a 15 percent reduction of new infections over the past decade and a 22 percent decline in AIDS-related deaths in the last five years," a WHO press release reports.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme, the most malignant cancer of the brain.
Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Spectranetics Corporation today initiated a voluntary recall of specific lots of its thrombus extraction catheter (product number 60090-01) manufactured by Spectranetics since October 2009. The Food and Drug Administration has been informed of this action and communication to various Competent Authorities outside of the United States has begun. While Spectranetics has received and confirmed customer complaints on this issue, no adverse events have been reported to the Company.
› Verified 9 days ago
Dr. Andrea Badillo, MD Surgery Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2451 Fax: 202-476-4174 | |
Jerome Alain Byam, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1310 Southern Ave Se, Washington, DC 20032 Phone: 202-574-6000 | |
Dr. Steven Macht, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2021 K St Nw, #217, Washington, DC 20006 Phone: 202-887-8120 Fax: 202-887-8288 | |
Earl Hodin, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2151 | |
Dr. Brandon W Propper, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Washington, DC 20037 Phone: 202-741-3210 | |
David H Song, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Phc Building, First Floor, Washington, DC 20007 Phone: 202-444-8751 Fax: 202-444-7204 | |
Melissa Martinez Anastacio, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Room 4b42, Washington, DC 20010 Phone: 202-877-7259 Fax: 202-877-7258 |